A Phase 4 interventional study of Aflibercept (BAY86-5321, Eylea) in Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Bayer. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Bayer · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 24th largest by enrollment, is one of 5 that started in 2024, is one of 26 in phase 4, and was the 51st registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 5 started in 2024.
This study's enrollment of 51 is close to the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
16 studies in Macular Edema by Bayer: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Macular Edema by Bayer, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 4, and was the 15th registered.
Bayer’s Macular Edema studies by the year they started, since 2009.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
Among Bayer’s 16 in Macular Edema:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD).
DME is a diabetes-related eye disorder. In DME, the macula swells up due to fluid leakage from damaged blood vessels, resulting in vision problems. DME is a leading cause of vision loss in working age adults. nAMD is an eye disorder that causes vision loss due to the growth of abnormal blood vessels that leak blood or retinal fluid into the macula (the central part of the retina). nAMD is a leading cause of vision loss for people aged 50 and older.
The study treatment Aflibercept (also called BAY 86-5321) is a drug that blocks a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye.
The main purpose of this study is to to collect more information on the blood levels of aflibercept when 8 mg aflibercept is injected in both eyes of participants with DME or nAMD.
For this, the researchers will analyze Maximum observed concentration (Cmax): the highest amount of aflibercept in participants' blood will be measured after multiple doses of aflibercept during the study.
Participants will receive 8 mg aflibercept as injections into the vitreous cavity (jelly-like substance that fills the centre of the eye) of both eyes.
Participants will be divided into three groups and will receive initial and maintenance injections of 8 mg aflibercept in both eyes. Researchers will closely monitor the health of the participants during the study.
During the study, the doctors and their study team will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's enrollment of 51 is close to the median of 56 across 586 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 participants will be assigned to Regimen 1. Regimen 1 participants will be administered 8 mg aflibercept injections according to the Regimen 1 dosing schedule.
Drug: Aflibercept (BAY86-5321, Eylea)
Up to 15 participants will be assigned to Regimen 2. Regimen 2 participants will be administered 8 mg aflibercept injections according to the Regimen 2 dosing schedule.
Drug: Aflibercept (BAY86-5321, Eylea)
Up to 15 participants will be assigned to Regimen 3. Regimen 3 participants will be administered 8 mg aflibercept injections according to the Regimen 3 dosing schedule.
Drug: Aflibercept (BAY86-5321, Eylea)
8 mg, intravitreal injection
Also known as: BAY86-5321, Eylea HD
Maximum Observed Concentration (Cmax) of Free Aflibercept
Cmax was defined as the maximum observed plasma concentration of free aflibercept for each participant during the regimen-specific semi-dense pharmacokinetic sampling period. Concentrations were assessed at pre-dose and at Days 1, 3, 7, 14, and 28 after the relevant aflibercept administration. The relevant administration was the baseline bilateral administration for Regimen 1, the third same-day bilateral administration at Week 8 for Regimen 2, and the third administration to the second eye for Regimen 3, administered one week after the third administration to the first eye. For each regimen, the highest observed concentration across these sampling points was selected as the participant's Cmax. Participant-level Cmax values were summarized by treatment regimen.
Time frame: From pre-dose through 28 days after the regimen-specific aflibercept administration used for Cmax determination
| Milestone | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) |
|---|---|---|---|
| Started | 17 | 19 | 15 |
| Completed | 17 | 17 | 14 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
Cmax was defined as the maximum observed plasma concentration of free aflibercept for each participant during the regimen-specific semi-dense pharmacokinetic sampling period. Concentrations were assessed at pre-dose and at Days 1, 3, 7, 14, and 28 after the relevant aflibercept administration. The relevant administration was the baseline bilateral administration for Regimen 1, the third same-day bilateral administration at Week 8 for Regimen 2, and the third administration to the second eye for Regimen 3, administered one week after the third administration to the first eye. For each regimen, the highest observed concentration across these sampling points was selected as the participant's Cmax. Participant-level Cmax values were summarized by treatment regimen.
| ug/L | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Free Aflibercept | 322.09 ± 1.83 | 360.61 ± 1.72 | 466.48 ± 1.54 |
Collected over Collected from the start of study intervention until the EOS visit, up to 52 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen 1 (Initial Treatment and Maintenance) | 0/17 (0%) | 2/17 (11.8%) | 12/17 (70.6%) |
| Regimen 2 (Bilateral Simultaneous Treatment) | 0/19 (0%) | 2/19 (10.5%) | 10/19 (52.6%) |
| Regimen 3 (Bilateral Staggered Treatment) | 1/15 (6.7%) | 3/15 (20%) | 7/15 (46.7%) |
| Event | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/17 | 0/19 | 1/15 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/17 | 0/19 | 1/15 |
| Cerebrovascular accidentNervous system disorders | 0/17 | 0/19 | 1/15 |
| Coronary artery diseaseCardiac disorders | 1/17 | 0/19 | 0/15 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/17 | 0/19 | 0/15 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/17 | 1/19 | 0/15 |
| OrchitisInfections and infestations | 0/17 | 1/19 | 0/15 |
| Event | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/17 | 0/19 | 1/15 |
| COVID-19Infections and infestations | 2/17 | 0/19 | 0/15 |
| ConjunctivitisInfections and infestations | 2/17 | 0/19 | 0/15 |
| Cataract corticalEye disorders | 0/17 | 2/19 | 0/15 |
| Conjunctival haemorrhageEye disorders | 1/17 | 2/19 | 0/15 |
| Blood pressure increasedInvestigations | 1/17 | 2/19 | 1/15 |
| Intraocular pressure increasedInvestigations | 0/17 | 2/19 | 0/15 |
| Posterior capsule opacificationEye disorders | 0/17 | 0/19 | 1/15 |
| Vitreous detachmentEye disorders | 0/17 | 0/19 | 1/15 |
| Vitreous haemorrhageEye disorders | 0/17 | 0/19 | 1/15 |
| Age, Continuous(years) | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) | Total |
|---|---|---|---|---|
| Mean | 64.1 ± 12.8 | 67.9 ± 10.1 | 68.5 ± 11.3 | 66.8 ± 11.3 |
| Sex: Female, Male(Participants) | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) | Total |
|---|---|---|---|---|
| Female | 6 | 8 | 10 | 24 |
| Male | 11 | 11 | 5 | 27 |
| Race (NIH/OMB)(Participants) | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 17 | 19 | 15 | 51 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 17 | 19 | 15 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| nAMD / DME(Participants) | Regimen 1 (Initial Treatment and Maintenance) | Regimen 2 (Bilateral Simultaneous Treatment) | Regimen 3 (Bilateral Staggered Treatment) | Total |
|---|---|---|---|---|
| Neovascular age related macular degeneration (nAMD) | 5 | 12 | 4 | 21 |
| Diabetic macular edema (DME) | 12 | 7 | 11 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Sep 2024 to primary completion in Oct 2025, 13 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 63 phase 4 interventional studies under Macular Edema, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept